Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study
PaperCitations, authors & open-access status
Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 167 citations, 2023 year and green oa status.
167
Citations
2023
Year
green
OA Status